diabetic retinopathy and / or diabetic nephropathy.
Conditions
Interventions
Control:Conventional treatment, not taking the compound Danshen Dripping Pill
Sponsors
Shengjing Hospital of China Medical University, and Affiliated Hospital of Liaoning University of Chinese Traditional Medicine
Eligibility
Sex/Gender
All
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: The patient should meet the 1st to 4th criteria at the same time. And DR group must also satisfy the 5th criteria, DN group must meet 6th and 7th criteria. Patients who meet 8th criteria could enter either DR or DN group. 1. Diagnosed type 2 diabetic patients according to WHO standard in 1991; 2. Age range: 25-75, male or female; 3. Blood glucose and blood pressure should be under good control: HbA1c <9%, BP <140mmHg/90mmHg; serum lipid level is normal. Blood glucose and blood pressure in a normal range at least for half a month; 4. If the blood pressure, blood glucose or blood lipid is not meet the third criteria, allowing for half a month after the screening period; 5. Diabetic retinopathy (stage II ~ III microaneurysms, hemorrhage spot, yellow and white exudate, or macular edema); 6. DN group who have hypertension must use the ACEI or ARB agents for more than 2 weeks to control blood pressure; 7. DN group (phase III; the ratio of urine microalbumin to creatinine: 30 to 300 mg/g); 8. Both have diabetic retinopathy and diabetic nephropathy.
Exclusion criteria
Exclusion criteria: 1. Allergic to CDDP; 2. Severe hepatic impairment ( ALT, AST or TBil is higher than the limit of normal value of 3 times, allowing retest in one week later); 3. Severe heart disease, myocardial infarction, unstable angina, chronic heart failure (NYHA grade III and IV); 4. Severe renal impairment (Cr is higher than the limit of normal value of one time, allowing retest in one week later); 5. Mental disease or cognitive impairment patients; 6. Pregnant and lactating women, and women without normal contraceptive measures during the study period; 7. Urinary infection (urine routine test: WBC>=10/HP), and the infection still exist in two weeks later (urine routine test: WBC>=10/HP); 8. Participated (within three months) in or are in other clinical trials; 9. Patients could not take medicine on time; 10. Other reasons not for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urine microalbumin / (creatinine);Microhemangioma;Bleeding sopt;The visual acuity;hard (soft) exudate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood glucose;Blood pressure;HbA1c; | — |
Countries
China
Contacts
Public ContactHan Ping, Yu Shijia
Outcome results
None listed